Incannex Healthcare Limited American Depositary Shares

Incannex Healthcare Limited engages in the research development and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies in Australia. It offers APIRx-1801 an ultrapure tetrahydrocannabinol; APIRx-1802 an ultrapure CBD; and APIRx-1803 an ultrapure cannabigerol. The company also develops IHL-42X which has completed Phase IIa clinical trial for obstructive sleep apnea; Psi-GAD that is in Phase IIa clinical trial for generalized anxiety disorder; MedChew Dronabinol which has completed Phase Ia clinical trial for nausea and vomiting in chemotherapy; CanChew Plus that has completed Phase IIa clinical trial for irritable bowel syndrome; APIRx-1601 which has completed Phase IIa clinical trial for vitiligo; APIRx-1602 that has completed Phase IIa clinical trial for psoriasis; and APIRx-1603 which has completed Phase IIa clinical trial for atopic dermatitis. In addition its product portfolio includes IHL-675A for inflammatory lung disease IHL-675A for rheumatoid arthritis IHL-675A for inflammatory bowel disease and IHL-216A for traumatic brain injury/concussion which have completed pre-clinical trials; and MedChew 1401 for pain and spasticity in multiple sclerosis MedChew GB for post-herpatic neuralgia MedChew-1502 for Parkinson's disease MedChew-1503 for dementia MedChew RL for restless legs syndrome APIRx 1505 Flotex for chrohn's disease CanChew RX and SuppoCan (Suppository) for inflammatory bowel disease CheWell for addiction of cannabis CanQuit for tobacco smoking cessation CanQuit O for opioid addiction APIRx-1701 for glaucoma and APIRx-1702 for dry eye syndrome that are in pre-clinical trials. The company was formerly known as Impression Healthcare Limited and changed its name to Incannex Healthcare Limited in June 2020. Incannex Healthcare Limited was incorporated in 2001 and is based in Melbourne Australia.